AI English summary of an SEC filing — figures as filed
Leidos LDOSLeidos said its second quarter of fiscal 2024 revenue was $4,132 million, net income was $324 million ($2.37 per diluted share), and adjusted EBITDA (non-GAAP) was $559 million, with a margin of 13.5%. The quarter ended June 28, 2024 and covered 3 months.
Key points
AI summaryLeidos said its second quarter of fiscal 2024 revenue was $4,132 million, net income was $324 million ($2.37 per diluted share), and adjusted EBITDA (non-GAAP) was $559 million, with a margin of 13.5%. The quarter ended June 28, 2024 and covered 3 months.
The company said Health & Civil segment revenue for Q2 was $1.26 billion, up 22% from the prior-year quarter, and its operating income margin was 24.3% (13.0% a year earlier). The company cited increased volumes and case complexity in its managed health services business, along with better incentive performance, as the drivers.
Leidos said it generated $374 million of net cash from operating activities in Q2. After $23 million in property, equipment and software payments, quarterly free cash flow (non-GAAP) was $351 million. The company returned $165 million to shareholders, including $114 million in share repurchases and $51 million in regular quarterly cash dividends.
Leidos updated its full-year 2024 fiscal guidance, with revenue of $16.1 billion to $16.4 billion (previously $16.0 billion to $16.4 billion) and non-GAAP diluted EPS of $8.60 to $9.00 (previously $8.40 to $8.80). Adjusted EBITDA margin is approximately 12%, compared with the prior mid-to-high 11%.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 Revenue, Net Income and Adjusted EBITDA
Leidos said its second quarter of fiscal 2024 revenue was $4,132 million, net income was $324 million ($2.37 per diluted share), and adjusted EBITDA (non-GAAP) was $559 million, with a margin of 13.5%. The quarter ended June 28, 2024 and covered 3 months.
Source · Based on the filing body and exhibits
Health & Civil Segment Results and Company Explanation
The company said Health & Civil segment revenue for Q2 was $1.26 billion, up 22% from the prior-year quarter, and its operating income margin was 24.3% (13.0% a year earlier). The company cited increased volumes and case complexity in its managed health services business, along with better incentive performance, as the drivers.
Source · Based on the filing body and exhibits
Q2 Cash Flow and Shareholder Returns
Leidos said it generated $374 million of net cash from operating activities in Q2. After $23 million in property, equipment and software payments, quarterly free cash flow (non-GAAP) was $351 million. The company returned $165 million to shareholders, including $114 million in share repurchases and $51 million in regular quarterly cash dividends.
Source · Based on the filing body and exhibits
Updated Full-Year 2024 Guidance
Leidos updated its full-year 2024 fiscal guidance, with revenue of $16.1 billion to $16.4 billion (previously $16.0 billion to $16.4 billion) and non-GAAP diluted EPS of $8.60 to $9.00 (previously $8.40 to $8.80). Adjusted EBITDA margin is approximately 12%, compared with the prior mid-to-high 11%.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…